GLP-3R vs Tirzepatide
GLP-3R and Tirzepatide are both incretin-based research peptides studied for metabolic regulation and administered subcutaneously in research protocols. GLP-3R is studied as a triple agonist at the GLP-1, GIP, and glucagon receptors, while Tirzepatide is studied as a dual agonist at the GLP-1 and GIP receptors. The glucagon receptor component is the main mechanistic distinction, and research explores whether it contributes an energy expenditure effect alongside appetite signaling. GLP-3R has been studied for body weight reduction in obesity, glycemic control in type 2 diabetes, and liver fat in metabolic dysfunction-associated steatotic liver disease. Tirzepatide has been evaluated in multiple phase 3 trials for glycemic control, weight reduction and maintenance, and a head-to-head comparison with semaglutide.
Key differences
- 01
GLP-3R is studied at three receptors (GLP-1R, GIPR, and GCGR), whereas Tirzepatide is studied at two (GLP-1R and GIPR).
- 02
The glucagon receptor activity studied with GLP-3R has been explored for a possible contribution to energy expenditure, while Tirzepatide research centers on combined incretin effects on insulin signaling, gastric emptying, and satiety.
- 03
Tirzepatide has been evaluated in multiple randomized phase 3 trials, including SURPASS-1, SURPASS-2, and SURMOUNT-4, while GLP-3R has one published randomized phase 3 trial in type 2 diabetes alongside phase 2 work, and long-term human safety data for it remain limited.
- 04
Research protocols for GLP-3R have used 500 to 4,000 mcg once weekly, stepping up from 1 mg to 4 mg by week 9, compared with 1.5 to 15 mg once weekly for Tirzepatide, stepping up from 2.5 mg to 10 mg by week 13.
- 05
Tirzepatide research includes a cardiovascular outcomes trial against dulaglutide, whereas GLP-3R registrational trial designs include obstructive sleep apnea and knee osteoarthritis.
Side by side
Triple GLP/GIP/Glucagon — max fat loss, appetite control
Dual GLP-1/GIP — appetite control, metabolic support
Late clinical
Late clinical
Performance
Performance
Subcutaneous
Subcutaneous
Research protocols have used 500–4,000 mcg per administration, once weekly (morning, fasted), stepping up from 1 mg to 4 mg by week 9. Reported cycle: continuous until target weight loss; long-term non-weight-loss model: 1mg weekly.
Research protocols have used 1.5–15 mg per administration, once weekly (morning, fasted), stepping up from 2.5 mg to 10 mg by week 13. Reported cycle: continuous until target weight loss.
- Body weight reduction in adults with obesity
- Glycemic control in type 2 diabetes
- Liver fat in metabolic dysfunction-associated steatotic liver disease
- Obstructive sleep apnea and knee osteoarthritis in registrational trial designs
- Glucagon receptor contribution to energy expenditure
- Glycemic control in type 2 diabetes trials
- Weight reduction and weight maintenance in adults with obesity
- Appetite, energy intake, and fat mass
- Head-to-head comparison with semaglutide
- Metabolic dysfunction-associated steatohepatitis with liver fibrosis
- Cardiovascular outcomes compared with dulaglutide
- Safety has been assessed in randomized phase 2 and phase 3 trials, though specific adverse events are not summarized on this page
- Long-term human safety data remain limited while registrational trials continue
- No regulatory approval for any indication has been reported
- Safety was a primary focus of phase 3 trials such as SURPASS-1, though specific adverse event rates are not summarized here
- Cardiovascular safety is being assessed against dulaglutide in the SURPASS-CVOT trial
- Studied for effects on gastric emptying as part of its mechanism
- Long-term safety outside controlled trial settings is not characterized in this overview
5 cited studies
5 cited studies
Studied ranges describe what published research protocols have used. They are not instructions or recommendations. Products are sold for research purposes only; each order ships with a protocol guide for the specific product.
Mechanism
GLP-3R
Research investigates GLP-3R across three receptors: GLP-1 and GIP for glucose-dependent insulin signaling and satiety, and glucagon for its association with energy expenditure.
Triple Agonism
Studied at three distinct metabolic receptors, the glucagon component being what separates it from dual agonists.
Energy Expenditure
Explored for whether glucagon receptor activity contributes an expenditure effect alongside appetite signaling.
Tirzepatide
Research investigates tirzepatide across both incretin receptors, studied for combined effects on insulin signaling, gastric emptying, and satiety.
Dual Incretin
Studied at both GIP and GLP-1 receptors, the GIP component distinguishing it from single agonists.
Metabolic Signaling
Explored for effects across glucose handling and appetite regulation together.
